ph: 09 535 7218
f
TAGS
H

Rivaroxaban funding

Rivaroxaban not indicated or funded before POAC DVT scan

In line with the Auckland Regional HealthPathway, when there is a delay in obtaining community ultrasound for DVT, Enoxaparin continues to be the medication to be administered and funded through POAC.

The issue of using rivaroxaban instead of enoxaparin for anticoagulation coverage whist awaiting ultrasound for DVT was considered when the pathways were updated upon the PHARMAC funding of rivaroxaban. However, rivaroxaban use for this indication would be off licence and is not recommended by the region’s Haematologists.

Please continue to administer Enoxaparin, which POAC will fund as indicated if there is a delay >6 hours in obtaining an DVT ultrasound scan  in line with the pathway –see DVT



 

This product has been added to your cart

CHECKOUT